ERBB2 and breast carcinoma: The continuous development and successful marketing of anti-HER2 therapeutics [such as monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody–drug conjugates (ADCs)] have achieved good clinical efficacy in treating HER2-positive breast cancer and have gradually changed clinical practice [2, 3].